Sunday 18 October 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
6.04
0.64
−9.58%
Follow AGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 2.01 | 1.16 |
P/S ratio |
1.15 | 0.82 | 1.02 | 0.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.33) | (5.62) | (3.52) | (4.05) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.44 | 1.39 | 1.17 | 1.22 | |
EV/EBITDA |
0.00 | 0.00 | 9.34 | 3.94 | |
EV/Operating CF |
(1.72) | (2.05) | (1.66) | (1.64) | |
EV/FCF |
(1.73) | (2.06) | (1.67) | (1.64) | |
Quick Ratio |
0.03 | 0.03 | 0.36 | 0.32 | |
Current Ratio |
0.47 | 0.41 | 0.38 | 0.34 | |
Net Debt/EBITDA |
(20.31) | 2.78 | (0.31) | 0.96 | |
Debt/Assets |
14.63% | 19.69% | 16.19% | 17.41% | |
Debt/Equity |
(0.12) | (0.16) | (0.13) | (0.15) | |
Asset Turnover |
0.45 | 0.50 | 0.64 | 0.74 | |
Operating CF/Net income |
(0.23) | 1.56 | (0.92) | 51.65 | |
Capex/Depreciation |
0.03 | 0.00 | 0.05 | 0.46 | |
Interest Coverage |
(0.35) | 0.90 | 1.03 | 0.74 | |
Research and Development Expense of Revenue |
78.04% | 21.96% | 35.04% | 42.76% | |
Selling, General and Administrative Expense of Revenue |
35.92% | 35.95% | 20.33% | 24.53% | |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.15 | 0.16 | |
Share Based Compensation of Revenue |
10.72% | 10.12% | 3.25% | 10.45% | |
Graham Net Nets |
(3.10) | (3.98) | (2.52) | (2.37) | |
Graham Number |
20.25 | 9.17 | 0.00 | 0.00 | |
Earnings Yield |
(53.77%) | (12.74%) | 49.70% | 86.48% | |
Free Cash Flow Yield |
(72.46%) | (82.30%) | (68.76%) | (77.60%) | |
Revenue per Share |
0.95 | 1.15 | 0.89 | 0.84 | |
Operating CF per Share |
(0.46) | (0.56) | (0.95) | (0.75) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Free Cash Flow per Share |
(0.46) | (0.56) | (0.95) | (0.75) | |
Cash per Share |
0.11 | 0.10 | 0.92 | 0.45 | |
Shareholders Equity per Share |
(8.81) | (9.34) | (6.01) | (4.98) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(8.81) | (9.34) | (6.01) | (4.98) | |
Free Cash Flow |
(14.66) | (16.62) | (35.92) | (30.96) | |
Working Capital |
(153.18) | (190.05) | (153.95) | (153.01) | |
Capital Expenditures |
0.08 | 0.00 | 0.03 | 0.24 | |
Net Current Asset Value |
(380.81) | (371.22) | (319.15) | (299.73) | |
EV/EBIT |
0.00 | 0.00 | 17.75 | 4.46 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 15.46 | 3.49 | |
| Other line items | |||||
Average Receivables |
3.24 | 3.71 | 27.21 | 27.96 | |
Average Payables |
65.59 | 72.23 | 67.66 | 66.69 | |
Average Assets |
236.19 | 226.53 | 193.33 | 178.96 | |
Average Common Equity |
(276.34) | (292.14) | (275.19) | (271.08) |
Columns are period end dates